Jakob Loven Biography and Net Worth

Director of Kronos Bio

Mr. Jakob Loven is the Director of Kronos Bio.

How do I contact Jakob Loven?: The corporate mailing address for Mr. Loven and other Kronos Bio executives is , , . Kronos Bio can also be reached via phone at 650-781-5200 and via email at media@kronosbio.com. Learn More on Jakob Loven's contact information.
Has Jakob Loven been buying or selling shares of Kronos Bio?: Jakob Loven has not been actively trading shares of Kronos Bio in the last ninety days. Most recently, Jakob Loven sold 14,004 shares of the business's stock in a transaction on Monday, April 19th. The shares were sold at an average price of $20.59, for a transaction totalling $288,342.36. Learn More on Jakob Loven's trading history.
Who are Kronos Bio's active insiders?: Kronos Bio's insider roster includes Norbert Bischofberger (CEO), Marianne De Backer (Director), Jorge DiMartino (VP), Christopher Dinsmore (Insider), and Jakob Loven (Director). Learn More on Kronos Bio's active insiders.
Are insiders buying or selling shares of Kronos Bio?: During the last year, Kronos Bio insiders bought shares 3 times. They purchased a total of 2,671,662 shares worth more than $2,787,697.16. The most recent insider tranaction occured on June, 27th when CEO Norbert W Bischofberger bought 410,848 shares worth more than $480,692.16. Insiders at Kronos Bio own 24.4% of the company. Learn More about insider trades at Kronos Bio.
Information on this page was last updated on 6/27/2024.

Jakob Loven Insider Trading History at Kronos Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/19/2021	Sell	14,004	$20.59	$288,342.36
4/16/2021	Sell	33,162	$21.01	$696,733.62
4/14/2021	Sell	32,636	$22.80	$744,100.80
4/12/2021	Sell	15,828	$26.28	$415,959.84
4/8/2021	Sell	63,128	$27.41	$1,730,338.48

Jakob Loven Buying and Selling Activity at Kronos Bio

Kronos Bio Company Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Today's Range

Now: $0.81

$0.81

$0.85

50 Day Range

MA: $0.96

$0.82

$1.07

2 Week Range

Now: $0.81

$0.69

$1.60

Volume

109,846 shs

Average Volume

269,933 shs

Market Capitalization

$49.26 million

P/E Ratio

N/A

Dividend Yield